{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:56:43Z","timestamp":1785455803193,"version":"3.56.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bbcan.2021.188639","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T18:01:37Z","timestamp":1634925697000},"page":"188639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients"],"prefix":"10.1016","volume":"1876","author":[{"given":"Izabela","family":"Szulc-Kielbik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kielbik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Klink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2021.188639_bb0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cyto.2012.01.015","article-title":"Inflammation and ovarian cancer","volume":"58","author":"Macci\u00f2","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.bbcan.2021.188639_bb0015","article-title":"Relationship between inflammation and cancer progression: recent advances in interleukin-6 signaling and its blockage in cancer therapy","volume":"1","author":"Nagasaki","year":"2014","journal-title":"Recept. Clin. Invest."},{"key":"10.1016\/j.bbcan.2021.188639_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.bbcan.2021.188639_bb0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","article-title":"Interleukin-6: biology, signaling and strategies of blockade","volume":"26","author":"Schaper","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbcan.2021.188639_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbamcr.2004.03.001","article-title":"Activation of the Interleukin-6 promoter by a dominant negative mutant of c-Jun","volume":"1692","author":"Faggioli","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2021.188639_bb0035","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fimmu.2016.00604","article-title":"Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms","volume":"7","author":"Luo","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0040","doi-asserted-by":"crossref","first-page":"18138","DOI":"10.1074\/jbc.M000379200","article-title":"Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation","volume":"275","author":"Terry","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2021.188639_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neulet.2004.03.008","article-title":"Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer\u2019s disease","volume":"362","author":"Zhang","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbcan.2021.188639_bb0050","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.ATV.0000194099.65024.17","article-title":"Interleukin 6\u2013174 g\/c promoter polymorphism and risk of coronary heart disease: results from the Rotterdam study and a meta-analysis","volume":"26","author":"Sie","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/02648725.2013.801236","article-title":"Post-transcriptional regulation of cytokine mRNA controls the initiation and resolution of inflammation","volume":"29","author":"Mino","year":"2013","journal-title":"Biotechnol. Genet. Eng. Rev"},{"key":"10.1016\/j.bbcan.2021.188639_bb0060","first-page":"878","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"2011","author":"Scheller","year":"1813","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2021.188639_bb0065","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5301\/jsrd.5000265","article-title":"Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis","volume":"2","author":"Choy","year":"2017","journal-title":"J. Scleroderma Related Disorders"},{"key":"10.1016\/j.bbcan.2021.188639_bb0070","doi-asserted-by":"crossref","first-page":"E3062","DOI":"10.3390\/ijms21093062","article-title":"Immunological mechanisms in inflammation-associated colon carcinogenesis","volume":"21","author":"Hirano","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2021.188639_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbcan.2021.188639_bb0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v5.i2.231","article-title":"Regulation and function of signal transducer and activator of transcription 3","volume":"5","author":"Qi","year":"2014","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2021.188639_bb0085","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2021.188639_bb0090","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2021.188639_bb0095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.bbcan.2021.188639_bb0100","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.2147\/CMAR.S179189","article-title":"IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis","volume":"10","author":"Browning","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0105","first-page":"365","article-title":"Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells","volume":"2","author":"Wang","year":"2005","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0110","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00109-013-1080-7","article-title":"The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications\u2013a review","volume":"91","author":"Macci\u00f2","year":"2013","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.bbcan.2021.188639_bb0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/0300891618784790","article-title":"IL-6\/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer","volume":"105","author":"Yousefi","year":"2019","journal-title":"Tumori"},{"key":"10.1016\/j.bbcan.2021.188639_bb0120","series-title":"Tumor Metastasis","article-title":"Ovarian cancer metastasis: a unique mechanism of dissemination","author":"Mitra","year":"2016"},{"key":"10.1016\/j.bbcan.2021.188639_bb0125","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","article-title":"An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment","volume":"38","author":"Motohara","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2021.188639_bb0130","doi-asserted-by":"crossref","first-page":"E757","DOI":"10.3390\/jcm8060757","article-title":"Snail1: a transcriptional factor controlled at multiple levels","volume":"8","author":"Baulida","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbcan.2021.188639_bb0135","doi-asserted-by":"crossref","first-page":"E1118","DOI":"10.3390\/cells8101118","article-title":"The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges","volume":"8","author":"Loh","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2021.188639_bb0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0145","doi-asserted-by":"crossref","first-page":"E104","DOI":"10.3390\/cancers9080104","article-title":"Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer","volume":"9","author":"Klymenko","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2021.188639_bb0150","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/ijc.24901","article-title":"Snail is critical for tumor growth and metastasis of ovarian carcinoma","volume":"126","author":"Jin","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2021.188639_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cyto.2012.04.020","article-title":"Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells","volume":"59","author":"Wang","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.bbcan.2021.188639_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108334","article-title":"IL-6 and IL-8 are involved in JMJD2A-regulated malignancy of ovarian cancer cells","volume":"684","author":"Zhang","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbcan.2021.188639_bb0165","doi-asserted-by":"crossref","first-page":"83148","DOI":"10.18632\/oncotarget.13074","article-title":"Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2021.188639_bb0170","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3892\/ijo.2015.3122","article-title":"Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition","volume":"47","author":"So","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0175","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.7150\/jca.16116","article-title":"Interleukin-6 from ovarian mesenchymal stem cells promotes proliferation, sphere and Colony formation and tumorigenesis of an ovarian cancer cell line SKOV3","volume":"7","author":"Ding","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2021.188639_bb0180","first-page":"2081","article-title":"CAFs enhance paclitaxel resistance by inducing EMT through the IL-6\/JAK2\/STAT3 pathway","volume":"39","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2021.188639_bb0185","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5625\/lar.2015.31.4.188","article-title":"Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells","volume":"31","author":"Oh","year":"2015","journal-title":"Lab. Anim. Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13402-015-0251-7","article-title":"IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3\u2019-diindolylmethane in ovarian cancer cells","volume":"39","author":"Zou","year":"2016","journal-title":"Cell Oncol. (Dordr)"},{"key":"10.1016\/j.bbcan.2021.188639_bb0195","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4143\/crt.2016.175","article-title":"Adipose stromal cells from visceral and subcutaneous fat facilitate migration of ovarian cancer cells via IL-6\/JAK2\/STAT3 pathway","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2021.188639_bb0200","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/497429","article-title":"Treatment for recurrent ovarian cancer-at first relapse","volume":"2010","author":"Ushijima","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0205","article-title":"Ovarian cancers: genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells","volume":"5","author":"Testa","year":"2018","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.bbcan.2021.188639_bb0210","series-title":"Ovarian Cancer - A Clinical and Translational Update","first-page":"205","article-title":"Molecular mechanisms of platinum resistance in ovarian cancer","author":"Tapia","year":"2013"},{"key":"10.1016\/j.bbcan.2021.188639_bb0215","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.18632\/oncotarget.14021","article-title":"Chemoresistance and targeted therapies in ovarian and endometrial cancers","volume":"8","author":"Brasseur","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2021.188639_bb0220","first-page":"2596","article-title":"Different mechanisms underlie IL-6 release in chemosensitive and chemoresistant ovarian carcinoma cells","volume":"10","author":"De Marco","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0225","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00109-012-0946-4","article-title":"Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2","volume":"91","author":"Cohen","year":"2013","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.bbcan.2021.188639_bb0230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2010.02.019","article-title":"Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells","volume":"295","author":"Wang","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2021.188639_bb0235","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3892\/ijo.2014.2808","article-title":"Inhibition of IL-6\/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells","volume":"46","author":"Suh","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0240","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbrc.2013.04.087","article-title":"Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells","volume":"435","author":"Han","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2021.188639_bb0245","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/CAD.0000000000000149","article-title":"Nitric oxide donors reduce the invasion ability of ovarian cancer cells in vitro","volume":"25","author":"Kielbik","year":"2014","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bbcan.2021.188639_bb0250","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0255","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0260","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting Interleukin-6 signaling in clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2021.188639_bb0265","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Guo","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2021.188639_bb0270","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","article-title":"Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer","volume":"16","author":"Guo","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0275","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","article-title":"Interleukin-6 as a therapeutic target in human ovarian cancer","volume":"17","author":"Coward","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0280","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mc.22325","article-title":"Antitumor effects of interleukin-6 (IL-6)\/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary","volume":"55","author":"Yanaihara","year":"2016","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbcan.2021.188639_bb0285","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer","volume":"26","year":"2015","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.bbcan.2021.188639_bb0290","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1078-0432.CCR-13-2200","article-title":"A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors","volume":"20","author":"Angevin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13048-020-00624-9","article-title":"Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS)","volume":"13","author":"Farkas","year":"2020","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0300","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ejca.2011.03.026","article-title":"Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer","volume":"47","author":"Yigit","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2021.188639_bb0305","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/172460080702200302","article-title":"Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual\/recurrent disease examination","volume":"22","author":"Chechlinska","year":"2007","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.bbcan.2021.188639_bb0310","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12885-015-1511-7","article-title":"Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers","volume":"15","author":"Lane","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2021.188639_bb0315","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/OTT.S73438","article-title":"Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions","volume":"8","author":"Chudecka-G\u0142az","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bbcan.2021.188639_bb0320","doi-asserted-by":"crossref","first-page":"1715064","DOI":"10.1155\/2020\/1715064","article-title":"Prognostic and clinical value of interleukin 6 and CD45+CD14+ inflammatory cells with PD-L1+\/PD-L2+ expression in patients with different manifestation of ovarian cancer","volume":"2020","author":"Wertel","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0325","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13309","article-title":"IL6, IL8, and IL10 in the distinction of malignant ovarian neoplasms and endometriomas","volume":"84","author":"Crispim","year":"2020","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2008.09.043","article-title":"A serum based analysis of ovarian epithelial tumorigenesis","volume":"112","author":"Nolen","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0335","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/humrep\/deg321","article-title":"Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours","volume":"18","author":"Dara\u00ef","year":"2003","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.bbcan.2021.188639_bb0340","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-06-1828","article-title":"Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7","volume":"13","author":"Lambeck","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0345","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5152\/jtgga.2011.54","article-title":"Determination of serum CRP, VEGF, leptin, CK-MB, CA-15-3 and IL-6 levels for malignancy prediction in adnexal masses","volume":"12","author":"Sen","year":"2011","journal-title":"J. Turk. Ger. Gynecol. Assoc"},{"key":"10.1016\/j.bbcan.2021.188639_bb0350","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1479-5876-10-45","article-title":"Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women","volume":"10","author":"Autelitano","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2021.188639_bb0355","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cyto.2015.01.035","article-title":"Plasma immune analytes in patients with epithelial ovarian cancer","volume":"73","author":"Block","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.bbcan.2021.188639_bb0360","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/s41598-020-59009-z","article-title":"Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer","volume":"10","author":"Kampan","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2021.188639_bb0365","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1055-9965.EPI-04-0404","article-title":"Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer","volume":"14","author":"Gorelik","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.bbcan.2021.188639_bb0370","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2009.03.028","article-title":"p53 autoantibodies, cytokine levels and ovarian carcinogenesis","volume":"114","author":"Tsai-Turton","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0375","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1158\/1055-9965.EPI-10-1180","article-title":"Circulating inflammation markers and risk of epithelial ovarian cancer","volume":"20","author":"Clendenen","year":"2011","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.bbcan.2021.188639_bb0380","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1177\/1933719112466299","article-title":"Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer","volume":"20","author":"C\u00e2ndido","year":"2013","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.bbcan.2021.188639_bb0385","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1158\/1055-9965.EPI-14-1279-T","article-title":"Inflammatory markers and risk of epithelial ovarian cancer by tumor subtypes: the EPIC cohort","volume":"24","author":"Ose","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.bbcan.2021.188639_bb0390","doi-asserted-by":"crossref","DOI":"10.4238\/gmr.15027936","article-title":"Effects of the balance between type 1 and type 2 T helper cells on ovarian cancer","volume":"15","author":"Hao","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imbio.2017.10.021","article-title":"Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients","volume":"223","author":"Nowak","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.bbcan.2021.188639_bb0400","first-page":"2322","article-title":"A study on changes and clinical significance of blood glucose, blood lipid and inflammation in patients with ovarian cancer","volume":"24","author":"Li","year":"2019","journal-title":"J. BUON"},{"key":"10.1016\/j.bbcan.2021.188639_bb0405","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0753-3322(01)00079-8","article-title":"Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients","volume":"55","author":"Kovacs","year":"2001","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2021.188639_bb0410","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.ejca.2015.07.012","article-title":"Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma","volume":"51","author":"Matsuo","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2021.188639_bb0415","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-11-210","article-title":"Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients","volume":"11","author":"Lane","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2021.188639_bb0420","first-page":"566","article-title":"Profiling of cytokines in human epithelial ovarian cancer ascites","volume":"2","author":"Matte","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0425","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2018.03.019","article-title":"Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients","volume":"482","author":"Dalal","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbcan.2021.188639_bb0430","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2015.05.009","article-title":"Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-\u03b1 and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer","volume":"138","author":"Kolomeyevskaya","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2021.188639_bb0435","first-page":"3673","article-title":"Inflammatory and nutritional serum markers as predictors of peri-operative morbidity and survival in ovarian cancer","volume":"37","author":"Kumar","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbcan.2021.188639_bb0440","doi-asserted-by":"crossref","first-page":"2873030","DOI":"10.1155\/2017\/2873030","article-title":"Markers of oxidative stress and inflammation in ascites and plasma in patients with platinum-sensitive, platinum-resistant, and platinum-refractory epithelial ovarian cancer","volume":"2017","author":"Cant\u00f3n-Romero","year":"2017","journal-title":"Oxid. Med. Cell Longev"},{"key":"10.1016\/j.bbcan.2021.188639_bb0445","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-19-0226","article-title":"Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without bevacizumab: results from GOG-0218","volume":"26","author":"Alvarez Secord","year":"2020","journal-title":"Clin. Cancer Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X21001372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X21001372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:54:12Z","timestamp":1759640052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X21001372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0304419X21001372"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2021.188639","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2021.188639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"188639"}}